FINWIRES · TerminalLIVE
FINWIRES

Johnson & Johnson Q1 Reinforces Growth Outlook on New Product Cycle, Morgan Stanley Says

By

Johnson & Johnson's (JNJ) Q1 results reinforced Morgan Stanley's confidence in the company's growth trajectory, driven by its new product cycle, including Icotyde.

The company reaffirmed its long-term outlook and sees a path to double-digit revenue growth by 2030. Johnson & Johnson also highlighted key Pharma growth drivers, including Icotyde, Rybrevant and Inlexzo. It further pointed to cardiovascular launches and the Orthopedics separation as tailwinds in MedTech.

Johnson & Johnson posted a Q1 beat and slightly lifted 2026 revenue guidance to $100.3 billion to $101.3 billion. This compares with Morgan Stanley's estimate of $101.1 billion and Street estimate of $100.6 billion. New adjusted EPS guidance was $11.45 to $11.65, versus Morgan Stanley's estimate of $11.82 and consensus of $11.56.

The company expects heavier investment in H1, with stronger earnings growth in H2 as new product launches scale, according to the note Tuesday.

Upcoming catalysts include additional readouts for Icotyde across plaque psoriasis and psoriatic arthritis. The company also expects data from the phase 2 Duet trials in ulcerative colitis and Crohn's disease. Phase 3 readouts of Milvexian in atrial fibrillation and secondary stroke prevention are also expected.

Morgan Stanley maintained an overweight rating on Johnson & Johnson and raised its price target to $283 from $267.

Price: $238.95, Change: $-1.15, Percent Change: -0.48%

Related Articles

Wire

GitLab Broadens Google Cloud Collaboration to Support AI Agents

GitLab (GTLB) said late Tuesday it expanded its collaboration with Alphabet's (GOOGL, GOOG) Google Cloud, allowing customers to use Google's Vertex AI models to power the GitLab Duo Agent Platform.The integration lets joint customers call Google's AI models directly inside GitLab, with that usage counting toward their existing Google Cloud spending commitments. GitLab said the move pairs Google's model performance with GitLab's built-in security, compliance and audit controls.GitLab shares rose 6.5% in after-hours trading, and Alphabet was little changed.

$GOOG$GOOGL$GTLB
Wire

TeraWulf Preliminary Q1 Revenue Misses Estimates; $800 Million Stock Offering Planned

TeraWulf (WULF) reported preliminary Q1 revenue late Tuesday of $30 million to $35 million and adjusted EBITDA of breakeven to $3 million.Analysts polled by FactSet expect revenue of $37.5 million and EBITDA of $7.6 million.Separately, the company announced an $800 million offering of common shares with underwriters granted a 30-day option to buy up to an additional $120 million in stock.Net proceeds will be used in part to finance a portion of the construction of a data center at its site in Hawesville, Kentucky.TeraWulf shares fell 7.3% in after-hours trading.

$WULF
Wire

Equity Bancshares Q1 Core EPS, Revenue Rise; Shares Fall After Hours

Equity Bancshares (EQBK) reported Q1 core earnings late Tuesday of $1.32 per diluted share, up from $0.90 a year earlier.Analysts polled by FactSet expected $1.16.Revenue in the three months ended March 31, expressed as the sum of net interest income and total noninterest income, rose to $83.2 million from $60.6 million a year earlier.Four analysts surveyed by FactSet expected $82.7 million.The company's shares fell 4.1% in after-hours trading.

$EQBK